The Food and Drug Administration (FDA) announced the issuance of an Emergency Use Authorization (EUA) under the Federal Food, Drug, and Cosmetic Act in response to an outbreak of monkeypox. FDA has issued an EUA for an in vitro diagnostic device as requested by Abbott Molecular, Inc. The EUA is effective as of October 7, 2022.
Opens in a new window
